in-PharmaTechnologist.com presents its periodic round-up of personnel changes in pharmaceutical manufacturing and development.
As part of the overhaul of its managerial structure Eli Lilly has made some new appointments. Tim Garnett will soon assume the role of vice president and chief medical officer. Reporting to Garnett will be Jen Stotka as the new vice president of global regulatory affairs and Don Therasse who has been appointed vice president of global patient safety. Having worked at Lilly for over 12 years Karim Bitar has now been appointed as president, European operations. Philippe Prufer will assume the new role of vice president and area director of European mid-size as well as central and eastern European markets following the consolidation of Europe into two areas from four. Eberhard Ludewigs will become vice president and area director of the expanded region covering Africa, the Middle East, the Commonwealth of Independent States (CIS) and Asian markets (other than China and Japan). Alexza Pharmaceuticals has appointed Jeffrey Williams as part-time president of Alexza Singapore. Williams will be responsible for establishing potential joint ventures in Singapore and initiating manufacturing operations for key components of Alexza's single-dose Staccato device in Singapore. Williams will remain as chief business officer for CoNCERT, Pharmaceuticals part-time. Prior to taking the post at CoNCERT Williams held senior vice president positions in manufacturing, operations, and corporate and business development for Alexza. SkyePharma has appointed Ken Cunningham to the post of CEO, succeeding Frank Condella. Cunningham worked closely with Condella in his previous role as chief operating officer of SkyePharma. Cunningham has held previous posts as CEO of Arakis, in addition to senior management and clinical development roles with Alza, Sequus, GlaxoSmithKline and Warner-Lambert. Pamela Cohen has been appointed as Kosan Biosciences senior vice president and chief medical officer. Cohen has experience in the global development and registration of cancer therapeutics. Cohen joins from GE Healthcare Medical Diagnostics where she held the post of global oncology therapeutic area head. She has also previously worked for Novartis. Integrated Project Services, a company offering engineering, construction management and compliance validation assistance to pharmaceutical and biotechnology companies has appointed Zenon Farion as director, biotechnology. Farion's knowledge of the industry should help the companies Biotech Process Engineering improve its technical and operations services for the development and commercialisation of biopharmaceutical products. Alan Krasner has been appointed to the post of chief medical officer at Biodel, a biopharmaceutical company involved in the development of treatments for endocrine disorders. Krasner was previously working at Pfizer global research and development in the position of director of the department of clinical research metabolic diseases. GlycoVaxyn, a company using glycoengineering to develop conjugated vaccines, has appointed Philippe Dro to the post of CEO. For nearly 20 years Dro has worked in the life science industry, during which time he was involved in executing strategic transactions at several biotech companies. Mark Varney has been promoted to CEO of Cortex Pharmaceuticals. Current CEO, Roger Stoll, will become the executive chairman of the board.
Varney has over fifteen years experience in the pharmaceutical industry, including posts at Cortex, Sepracor and Bionomics.